Total number of mice and rats used for research purposes according to the spanish decree RD 53/2013 definition of experimental procedure.
11,276
LAS animals used in research
101
LAS active procedures
306
ESU animals used in research
21
ESU active procedures
67
PIP active projects
2,277
BIOBANC new sample donations
29
BIOBANC Projects which asked for samples (Material Transfer Service)
39
BIOBANC Projects which asked for sample processing services
9,814
UAT services performed
49
UAT user groups (internal groups/external clients)
343
USIC active clinical trials/studies
94
USIC Num. Principal investigators
244
UEB new services
62
ARO active studies
LAB ANIMAL SERVICE (LAS)
Animals used in research
10,589
Mice
687
Rats
Active procedures per species
84
Mice
17
Rats
Total number of experimental procedures approved by the Competent Authority (Generalitat de Catalunya).
Active procedures per area and species
Annual average of cages and individuals/week
2,461
Mice
108
Rats
Average number of cages per week (maximum number of animals x cage =5)
EXPERIMENTAL SURGERY UNIT (ESU)
Animals used in research
225
Rabbits
32
Sheep
49
Pigs
Total number of pigs, sheep and rabbits used for research purposes according to the spanish decree RD 53/2013 definition of experimental procedure.
Active procedures per species
4
Rabbits
6
Sheep
10
Pigs
1
Ex vivo procedures (ESU)
Active procedures per area and species
PRECLINICAL IMAGING PLATFORM (PIP)
Optical imaging
| Research Groups | Acquiring Hours |
Quantification Hours | Research projects |
| VHIR | 164 | 6 | 13 |
| Pediatric Oncology | 1 | ||
| Translational Research in Child and Adolescent Cancer | 3 | ||
| Liver diseases | 3 | ||
| Infectious Diseases | 1 | ||
| Neurovascular diseases | 1 | ||
| Neurodegenerative diseases | 1 | ||
| Biomedical Research in Urology | 2 | ||
| Cardiovascular Diseases | 1 |
| VHIO | 439,00 | 28,25 | 20 |
| Stem Cells and Cancer | 3 | ||
| Preclinical and Translational Research Program | 5 | ||
| Growth Factors | 1 | ||
| Tumor biomarkers | 1 | ||
| Modeling of Anti-tumor Therapies | 5 | ||
| Cellular Plasticity and Cancer | 3 | ||
| Experimental Hematology | 2 |
| External users | 14 | 13,00 | 4 |
| Total hours | 617 | 47 | 37 |
Microct
| Research Groups | Studies (acquisition and analysis) | Research projects |
| VHIR | 364 | 4 |
| Nephrology and Kidney Transplant | 1 | |
| Pneumology | 1 | |
| Liver diseases | 1 | |
| Neurodegenerative diseases | 1 |
| VHIO | 238 | 8 |
| Stem Cells and Cancer | 1 | |
| Preclinical and Translational Research Program | 1 | |
| Modeling of Anti-tumor Therapies | 4 | |
| Cellular Plasticity and Cancer | 1 | |
| Radiomics | 1 |
| External users | 373 | 5 |
| Total acquisitions | 975 | 17 |
Ultrasound
| Research Groups | Studies (acquisition and analysis) | Research projects |
| VHIR | 443 | 4 |
| Neuromuscular and mitochondrial pathology | 1 | |
| Neurodegenerative diseases | 1 | |
| Cardiovascular Diseases | 2 |
| VHIO | 284 | 6 |
| Stem Cells and Cancer | 4 | |
| Experimental Hematology | 1 | |
| Cellular Plasticity and Cancer | 1 |
| External users | 246 | 2 |
| Total acquisitions | 973 | 12 |
BIOBANK
Number of new sample donations
| Cardiology Bank | 106 |
| Digestive Pathologies Bank | 14 |
| IMID: Immune Mediated Inflammatory Diseases | 216 |
| Immunology Bank | 599 |
| Nephrology Bank | 331 |
| Neurodegenerative Pathologies Bank | 63 |
| Neurological Tissue Bank | 5 |
| Obesity Bank | 427 |
| Pulmonar Bank | 120 |
| Sepsis Bank | 63 |
| Tumor Bank | 147 |
| Others | 186 |
| TOTAL NUMBER OF NEW SAMPLE DONATIONS | 2,277 |
Number of Projects which have asked for sample processing services
7
Cardiology Bank
1
Digestive Pathologies Bank
5
Immunology Bank
4
Nephrology Bank
1
Neurodegenerative Pathologies Bank
1
Neurological Tissue Bank
3
Obesity Bank
2
Pulmonary Bank
1
Sepsis Bank
2
Tumor Bank
12
Others
Number of Projects which have asked for samples (Material Transfer Service)
3
Cardiology Bank
2
Digestive Pathologies Bank
1
Fetal Tissue Bank
1
Gestational Pathologies Bank
4
Immunology Bank
1
Nephrology Bank
4
Neurodegenerative Pathologies Bank
3
Neurological Tissue Bank
1
Pulmonary Bank
3
Obesity Bank
3
Sepsis Bank
3
Tumor Bank
HIGH TECHNOLOGY UNIT (UAT)
User groups
39
Groups from VHIR
4
Partner Institutions
5
Public Research Organizations
2
Private Clients
Number of services performed (*)
490
Molecular Diagnosis
3,713
Genomics
3,354
Microscopy
1,595
Cytomics
662
Metabolomics
(*) The number of services for each platform is calculated by adding the number of units performed by each individual service within a platform. Internal and outsourced services managed by UAT are included.
Internal projects supported
| Nº of supported projects | % of service requests (**) | % of total income (***) | |
| Competitive funded projects | 124 | 73.81% | 83.17% |
| Non-competitive funded projects | 44 | 26.19% | 16.83% |
(**) Calculated over the total number of service requests charged to internal projects.
(***) Calculated over the UAT total income for fees charged to internal projects.
New internal services
| PLATFORM | SERVICE |
| Metabolomics | Development of different methods for detection and quantification of various endogenous metabolites and drugs in biological matrixes |
| Citometry |
New service: Luminex Magpix (protein/RNA multiplexed analysis) Customized design of antibody panels |
Training and educational activities
| Activities | ||
| qPCR-Introduction and advances (in collaboration with Thermo Fisher Scientific) | ||
| Introduction to panel design for flow citometry (in collaboration with Becton Dickinson) | ||
| A comprehensive view of microarrays and their applications in biomedical sciences (in collaboration with Thermo Fisher Scientific) | ||
| LightCycler 480_System and software (in collaboration with Roche) | ||
| Nanostring Technologies presentation: nCounter and GeoMx® Digital Spatial Profiler (in collaboration with Diagnostica Longwood/Nanostring) | ||
| Participation in the 48h OpenHouse Barcelona Festival | ||
CLINICAL RESEARCH SUPPORT UNIT (USIC)
Clinical areas of services performed by USIC
| USIC-Healthcare Platform | |
| Active clinical trials/studies | 343 |
| Services/Units of HUVH | 36 |
| No. principal investigators | 94 |
| No. of visits | 7,011 |
| No. intravenous treatments | 332 |
| No. spaces used for monitoring/auditories/center selection visits, start-up and close-out visits | 773 |
| % clinical trials USIC-Healthcare Area/ active clinical trials in HUVH | 24.9% |
| % of the use of healthcare spaces | 70% |
| Request of studies for medical consultation | 220 |
| Request of studies for day hospital | 43 |
| Request of studies for support of research nurse | 227 |
| Petitions of public funded studies | 54 |
| Petitions of private funded studies | 289 |
STATISTICS AND BIOINFORMATICS UNIT (UEB)
UEB Services by type
| UEB new services by type | TOTAL (€) | TOTAL (hores) | TOTAL (# serveis) |
| Teaching activities (Courses & Personalized) | 11,410.0 | 60 | 3 |
| High Throughput Data Analysis (Bioinformatics) | 25,887.9 | 996 | 13 |
| Data Analysis for Clinical Research (Biostatistics) | 26,273.4 | 1,011 | 75 |
| Statistical & methodological consultancy services | N/A | 309 | 67 |
| Database & applications development (REDCap ) | 9,269.0 | 357 | 40 |
| Clinical Trials data analysis | 26,790.1 | 1,030 | 6 |
| Regular Consultancy Collaborations | 42,200.0 | 1,623 | 2 |
| Budgets for grant proposals | 0.0 | 114 | 38 |
| TOTAL | 141,830.4 | 5,499.2 | 244.0 |
| UEB new services by user type* | TOTAL (€) | TOTAL (hours) | TOTAL (num services) |
| Internal | 87,524.0 | 3,366 | 228 |
| External | 42,900.8 | 1,381 | 46 |
| TOTAL | 130,424.8 | 4,747.7 | 274.0 |
| Active projects with UEB collaboration |
| EU-PEARL |
| VEIS |
| EOSC-LIFE |
| COVID TASK FORCE |
| Unitat Transveral de dades VH-VHIR |
ACADEMIC RESEARCH ORGANIZATION (ARO)
62
ARO active studies
Active studies by hospital service
Phases of the studies
4 (6.45%)
Phase I
5 (8.06%)
Phase I/II
10 (16.13%)
Phase II
15 (24.19%)
Phase III
15 (24.19%)
Phase IV
2 (3.23%)
Observational Study
10 (16.13%)
Other clinical Research
1 (1.61%)
Medical device
Clinical studies managed through networks
23 (37.10%)
SCReN
3 (4.84%)
ECRIN
36 (58.06%)
Out of networks
Promoter
6 (9.68%)
Medical Society
21 (33.87%)
VHIR
6 (9.68%)
Pharmaceutical Laboratories
25 (40.32%)
Hospital
1 (1.61%)
University
3 (4.84%)
Others
Development area
| National | 45 |
| International | 17 |
Centers participating
| Unicentric | 16 |
| Multicentric | 46 |
